ACTRN12622001532796尚未招募2 期
A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive delirium
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •A patient in one of the three participating ICU's will be eligible if they are 18 years of age or older and require pharmacological treatment for hyperactive delirium as indicated by administration of an anti-psychotic (during their initial ICU admission).
排除标准
- •Patients will be excluded if they were regularly taking an anti-psychotic medication prior to hospital admission or they have an allergy to either olanzapine or quetiapine.
研究者
相似试验
已完成
3 期
0.9% saline vs. Plasma-Lyte 148 for Intensive Care Fluid Therapy. (the SPLIT study)Intravenous Fluid Management in Critical IllnessCardiovascular - Other cardiovascular diseasesAnaesthesiology - Other anaesthesiologyInfection - Other infectious diseasesACTRN12613001370796Medical Research Institute of New Zealand2,500
进行中（未招募）
1 期
Gaviscon Double Action pH monitoring study.This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter.EUCTR2012-004131-23-GBReckitt Benckiser Healthcare (UK) Ltd25
进行中（未招募）
不适用
Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and doses of open label Sandostatin (100 µg t.i.d.) in acromegalic patientsAcromegaly is a rare, serious condition characterized by chronic hypersecretion of GH (growth hormone) caused in over 95% of patients by a GH-secreting pituitary adenoma. Clinical manifestations are due to excess GH and elevated IGF-I concentrations and/or the central pressure effects of the tumor mass. Clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality of patients.MedDRA version: 7.0Level: LLTClassification code 10000599EUCTR2004-002849-12-GBovartis Pharmaceuticals UK Ltd48
进行中（未招募）
不适用
Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and doses of open label Sandostatin (100 µg t.i.d.) in acromegalic patientsAcromegaly is a rare, serious condition characterized by chronic hypersecretion of GH (growth hormone) caused in over 95% of patients by a GH-secreting pituitary adenoma. Clinical manifestations are due to excess GH and elevated IGF-I concentrations and/or the central pressure effects of the tumor mass. Clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality of patients.MedDRA version: 7.0Level: LLTClassification code 10000599EUCTR2004-002849-12-ESovartis Farmaceutica S.A.48
进行中（未招募）
不适用
Extension to a multicentre, randomized, crossover, open labeldose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 mcg b.i.d.) and doses of open label of Sandostatin (100 mcg t.i.d.)in acromegalic patientsTreatment of patients with acromegaly in active phaseMedDRA version: 6.1Level: PTClassification code 10000599EUCTR2004-002849-12-ITOVARTIS FARMA